These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 34106794)

  • 1. Ixekizumab for the treatment of pediatric patients with moderate to severe plaque psoriasis.
    Cather JC; Young CT; Young MS; Cather JC
    Expert Opin Biol Ther; 2021 Aug; 21(8):983-990. PubMed ID: 34106794
    [No Abstract]   [Full Text] [Related]  

  • 2. Efficacy and safety of ixekizumab in a phase III, randomized, double-blind, placebo-controlled study in paediatric patients with moderate-to-severe plaque psoriasis (IXORA-PEDS).
    Paller AS; Seyger MMB; Alejandro Magariños G; Bagel J; Pinter A; Cather J; Keller S; Rodriguez Capriles C; Gontijo Lima R; Gallo G; Little CA; Edson-Heredia E; Li L; Xu W; Papp K;
    Br J Dermatol; 2020 Aug; 183(2):231-241. PubMed ID: 32316070
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of bodyweight on the efficacy and safety of ixekizumab: results from an integrated database of three randomised, controlled Phase 3 studies of patients with moderate-to-severe plaque psoriasis.
    Reich K; Puig L; Mallbris L; Zhang L; Osuntokun O; Leonardi C
    J Eur Acad Dermatol Venereol; 2017 Jul; 31(7):1196-1207. PubMed ID: 28370467
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics, Safety, and Efficacy of Ixekizumab in Chinese Patients with Moderate-to-Severe Plaque Psoriasis: A Phase 1, Single- and Multiple-Dose Study.
    Zheng M; Chen X; Wang F; Chen J; Jackson K; Yang F; Payne C; Li H; Wang Y; Xiao Z; Zheng J
    Adv Ther; 2023 Sep; 40(9):3804-3816. PubMed ID: 37356077
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Greater cumulative benefits from ixekizumab versus ustekinumab treatment over 52 weeks for patients with moderate-to-severe psoriasis in a randomized, double-blinded phase 3b clinical trial.
    Blauvelt A; Lomaga M; Burge R; Zhu B; Shen W; Shrom D; Dossenbach M; Pinter A
    J Dermatolog Treat; 2020 Mar; 31(2):141-146. PubMed ID: 30799638
    [No Abstract]   [Full Text] [Related]  

  • 6. Ixekizumab treatment improves fingernail psoriasis in patients with moderate-to-severe psoriasis: results from the randomized, controlled and open-label phases of UNCOVER-3.
    van de Kerkhof P; Guenther L; Gottlieb AB; Sebastian M; Wu JJ; Foley P; Morita A; Goldblum O; Zhang L; Erickson J; Ball S; Rich P
    J Eur Acad Dermatol Venereol; 2017 Mar; 31(3):477-482. PubMed ID: 27910156
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment outcomes with ixekizumab in patients with moderate-to-severe psoriasis who have or have not received prior biological therapies: an integrated analysis of two Phase III randomized studies.
    Gottlieb AB; Lacour JP; Korman N; Wilhelm S; Dutronc Y; Schacht A; Erickson J; Zhang L; Mallbris L; Gerdes S
    J Eur Acad Dermatol Venereol; 2017 Apr; 31(4):679-685. PubMed ID: 27696577
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of Ixekizumab Treatment on Depressive Symptoms and Systemic Inflammation in Patients with Moderate-to-Severe Psoriasis: An Integrated Analysis of Three Phase 3 Clinical Studies.
    Griffiths CEM; Fava M; Miller AH; Russell J; Ball SG; Xu W; Acharya N; Rapaport MH
    Psychother Psychosom; 2017; 86(5):260-267. PubMed ID: 28903122
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 12-week efficacy, safety and speed of response from a randomized, double-blinded trial.
    Blauvelt A; Papp K; Gottlieb A; Jarell A; Reich K; Maari C; Gordon KB; Ferris LK; Langley RG; Tada Y; Lima RG; Elmaraghy H; Gallo G; Renda L; Park SY; Burge R; Bagel J;
    Br J Dermatol; 2020 Jun; 182(6):1348-1358. PubMed ID: 31887225
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ixekizumab for treatment of adults with moderate-to-severe plaque psoriasis and psoriatic arthritis.
    Vu TT; Gooderham M; Papp K
    Expert Rev Clin Pharmacol; 2016 Nov; 9(11):1423-1433. PubMed ID: 27690669
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Population pharmacokinetic and exposure-efficacy analysis of ixekizumab in paediatric patients with moderate-to-severe plaque psoriasis (IXORA-PEDS).
    Jackson K; Chua L; Velez de Mendizabal N; Pitou C; Rodriguez Capriles C; Paller AS; Lansang P; Seyger MMB; Papp K;
    Br J Clin Pharmacol; 2022 Mar; 88(3):1074-1086. PubMed ID: 34378230
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improvements in psoriasis within different body regions vary over time following treatment with ixekizumab.
    Blauvelt A; Muram TM; See K; Mallinckrodt CH; Crowley JJ; van de Kerkhof P
    J Dermatolog Treat; 2018 May; 29(3):220-229. PubMed ID: 28792259
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ixekizumab treatment for psoriasis: integrated efficacy analysis of three double-blinded, controlled studies (UNCOVER-1, UNCOVER-2, UNCOVER-3).
    Papp KA; Leonardi CL; Blauvelt A; Reich K; Korman NJ; Ohtsuki M; Paul C; Ball S; Cameron GS; Erickson J; Zhang L; Mallbris L; Griffiths CEM
    Br J Dermatol; 2018 Mar; 178(3):674-681. PubMed ID: 28991370
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ixekizumab for the treatment of psoriasis: up-to-date.
    Craig S; Warren RB
    Expert Opin Biol Ther; 2020 Jun; 20(6):549-557. PubMed ID: 32050819
    [No Abstract]   [Full Text] [Related]  

  • 15. A 52-week, open-label study of the efficacy and safety of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with chronic plaque psoriasis.
    Gordon KB; Leonardi CL; Lebwohl M; Blauvelt A; Cameron GS; Braun D; Erickson J; Heffernan M
    J Am Acad Dermatol; 2014 Dec; 71(6):1176-82. PubMed ID: 25242558
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ixekizumab Improved Patient-Reported Genital Psoriasis Symptoms and Impact of Symptoms on Sexual Activity vs Placebo in a Randomized, Double-Blind Study.
    Yosipovitch G; Foley P; Ryan C; Cather JC; Meeuwis KA; Burge R; Bleakman AP; Lin CY; Malatestinic W; Gottlieb A
    J Sex Med; 2018 Nov; 15(11):1645-1652. PubMed ID: 30415816
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of Ixekizumab Treatment on Work Productivity for Patients With Moderate-to-Severe Plaque Psoriasis: Analysis of Results From 3 Randomized Phase 3 Clinical Trials.
    Armstrong AW; Lynde CW; McBride SR; Ståhle M; Edson-Heredia E; Zhu B; Amato D; Nikaï E; Yang FE; Gordon KB
    JAMA Dermatol; 2016 Jun; 152(6):661-9. PubMed ID: 26953848
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ixekizumab: A Review in Moderate to Severe Plaque Psoriasis.
    Syed YY
    Am J Clin Dermatol; 2017 Feb; 18(1):147-158. PubMed ID: 28138946
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of ixekizumab compared to etanercept and placebo in patients with moderate-to-severe plaque psoriasis and non-pustular palmoplantar involvement: results from three phase 3 trials (UNCOVER-1, UNCOVER-2 and UNCOVER-3).
    Menter A; Warren RB; Langley RG; Merola JF; Kerr LN; Dennehy EB; Shrom D; Amato D; Okubo Y; Reich K
    J Eur Acad Dermatol Venereol; 2017 Oct; 31(10):1686-1692. PubMed ID: 28322474
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of continuous every-2-week dosing of ixekizumab over 52 weeks in patients with moderate-to-severe plaque psoriasis in a randomized phase III trial (IXORA-P).
    Langley RG; Papp K; Gooderham M; Zhang L; Mallinckrodt C; Agada N; Blauvelt A; Foley P; Polzer P;
    Br J Dermatol; 2018 Jun; 178(6):1315-1323. PubMed ID: 29405255
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.